ADC Therapeutics S.A.

ADCTNYSEHealthcare● Active

$0.83

$-0.20(-19.04%)

Market Cap$106064575

P/E Ratio—

52W High$4.98

52W Low$0.7796

Avg Volume990K

Open$1.07

Beta1.77

Free Cash Flow Financials Revenue

ADC Therapeutics S.A. (ADCT) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

ADCT · free cash flow · updated Jun 8, 2026

Core FCF metrics

ADCT · FCF · TTM · margin & CAGR

Free cash flow was −$141.4M for FY2025 (fiscal year ending 2025-12-31), down 13.4% year-over-year The FCF margin was -173.8%.

FY2025 Free Cash Flow−$141.4M▼ -13.4% YoY

Trailing 12M (TTM)−$114.6Mtrailing 4 quarters sum

FCF Margin-173.8%−$141.4M ÷ revenue

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 8, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

ADCT · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest−$141.2M(0M)−$141.4M▼ 13.4%-173.8%

FY2024−$123.8M(1M)−$124.7M▼ 2.3%-176.0%

FY2023−$118.7M(3M)−$121.9M▲ +12.3%-175.3%

FY2022−$138.3M(1M)−$139.0M▲ +42.0%-66.2%

FY2021−$233.4M(6M)−$239.8M▼ 39.8%-706.9%

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

ADCT · P/FCF · FCF yield · FCF per share

ADC Therapeutics S.A. (ADCT) reported negative free cash flow of −$0.14B. FCF-based valuation ratios are not meaningful when FCF is negative.

FCF Yield (TTM)

N/A

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

N/A

TTM FCF ÷ Shares Outstanding

Price / FCF

N/A

Share Price ÷ FCF per Share

EV / FCF (TTM)

N/A

Enterprise Value basis

FCF-based valuation ratios are only meaningful when free cash flow is positive. Negative FCF indicates capital expenditures exceeded operating cash flow.

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

ADCT · cash flow statement · operating / investing / financing

For FY2025, ADC Therapeutics S.A. generated −$141.2M in operating cash flow and spent 0M in capital expenditures, yielding −$141.4M in free cash flow.

Operating Activities

−$141.2M

Cash from core business operations

2025-12-31

Investing Activities

+$0.4M

CapEx, acquisitions & investments

2025-12-31

Financing Activities

+$150.9M

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF (−$141.2M) − |CapEx| (0M) = FCF (−$141.4M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

ADCT vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

ADC Therapeutics S.A.YOU

ADCT

−$141.4M-13.4%-173.8%

Loss

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

ADC Therapeutics S.A. (ADCT) reported free cash flow of −$141.4M for FY2025 (fiscal year ending 2025-12-31), down 13.4% year-over-year. The FCF margin was -173.8%.

ADC Therapeutics S.A. has reported negative free cash flow in recent periods, indicating capital expenditures have exceeded operating cash flow. Data available for 9 fiscal years.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

ADCT free cash flow · 8 questions

ADC Therapeutics S.A. free cash flow was −$141.4M for FY2025, down 13.4% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at −$114.6M.

ADCT free cash flowADCT FCFADCT FCF 2025ADCT free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · ADC Therapeutics S.A. · ADC Therapeutics S.A. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026